Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30930616 | 1.00 | CYP2A6 (0.54) | CYP2A6CYP1A2PDPK1NPC1PLAU | |
| SCHEMBL21767440 | 0.78 | CLK4 (0.51) | NPC1RAB9ABIRC5 | |
| SCHEMBL5470573 | 0.74 | NPC1 (0.63) | CYP2A6CYP1A2PDPK1NPC1PLAU | |
| SCHEMBL28666568 | 0.73 | FGFR1 (0.39) | CYP2A6CYP1A2PDPK1PLAUKDM4E | |
| SCHEMBL16937582 | 0.73 | CYP2A6 (0.41) | CYP2A6HTR3A | |
| SCHEMBL31444206 | 0.73 | CYP1A2 (0.46) | CYP1A2TDP1MAPT | |
| SCHEMBL30184761 | 0.73 | FGFR1 (0.39) | CYP2A6CYP1A2PDPK1PLAUKDM4E | |
| SCHEMBL21608834 | 0.73 | HTT (0.57) | CYP1A2NPC1RAB9AKDM4EATM | |
| SCHEMBL17374951 | 0.73 | ALDH1A1 (0.54) | PDPK1PLAURAB9AHTR3AKDM4E | |
| SCHEMBL30381492 | 0.73 | HTT (0.57) | CYP1A2NPC1RAB9AKDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865932-B | Preparation method of benzothiophene sulfone compound with medicinal and fluorescent activity | BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-117865932-A | Preparation method of benzothiophene sulfone compound with medicinal and fluorescent activity | 北京化工大学 | 2024-04-12 | — | — | CN | claimed |
| CN-114409635-B | Compound and preparation method and application thereof | 五邑大学 | 2024-02-09 | — | — | CN | claimed |
| CN-114702515-B | Gold (III) complex and application thereof in cancer light therapy | 中山大学 | 2023-08-01 | — | — | CN | claimed |
| CN-114409635-A | Compound and preparation method and application thereof | 五邑大学 | 2022-04-29 | — | — | CN | claimed |
| CN-117865932-B | Preparation method of benzothiophene sulfone compound with medicinal and fluorescent activity | BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-122071494-A | Organic electroluminescent material and device | 环球展览公司 | 2026-05-22 | — | — | CN | disclosed |
| US-20260143905-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2026-05-21 | — | — | US | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | CEPHALON LLC (US) | 2025-10-14 | — | — | US | disclosed |
| WO-2025111513-A1 | COMPOUNDS USEFUL IN THE MODULATION OF KLHDC1 AND KLHDC2 ACTIVITY | NURIX THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-4558478-A1 | ARYL HYDROCARBON RECEPTOR AGONIST PRODRUGS AND METHODS OF USE THEREOF | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) | 2025-05-28 | — | — | EP | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5656643-A | QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-5409930-A | Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-25 | — | — | US | disclosed |
| EP-0584222-A4 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE POULENC RORER INT (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0584222-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE. | RHONE POULENC RORER INT (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | FASN, CES1, FADS2 | CYP2A6 165/4885CYP1A2 91/4885PDPK1 865/4885 |
| US-20260143905-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LBR, GLRB, GLRA1 | CYP2A6 4667/4885CYP1A2 4161/4885PDPK1 1778/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | CYP2A6 4581/4885CYP1A2 4771/4885PDPK1 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.